Browse Tag

covid19 vaccine candidate

Moderna coronavirus vaccine shows 94.5 % efficacy in Phase 3 trial

7 mins read

The FINANCIAL — Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the independent, NIH-appointed Data Safety Monitoring Board (DSMB) for the Phase 3 study of mRNA-1273, its vaccine candidate against COVID-19, has informed Moderna that the trial has met the statistical criteria pre-specified in the study protocol for efficacy, with a vaccine efficacy of 94.5%. This study, known as the COVE study, enrolled more than 30,000 participants in the U.S. and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of…

Read More »

Moderna coronavirus vaccine shows 94.5 % efficacy in Phase 3 trial

7 mins read

The FINANCIAL — Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the independent, NIH-appointed Data Safety Monitoring Board (DSMB) for the Phase 3 study of mRNA-1273, its vaccine candidate against COVID-19, has informed Moderna that the trial has met the statistical criteria…

Medicago and GSK announce start of Phase 2/3 clinical trials of adjuvanted COVID-19 vaccine candidate

3 mins read

The FINANCIAL — Medicago, a biopharmaceutical company headquartered in Quebec City, and GSK are pleased to announce the start of Phase 2/3 clinical trials of its plant-derived vaccine candidate for COVID-19 to evaluate its efficacy, safety, and immunogenicity.  Based on the positive Phase 1 results, Medicago has decided to launch the Phase 2/3 clinical trial…

Pfizer and BioNTech coronavirus vaccine candidate found to be more than 90% effective

7 mins read

The FINANCIAL — Pfizer Inc. and BioNTech SE (Nasdaq: BNTX) today announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the first interim efficacy analysis conducted on November 8, 2020 by an external, independent Data Monitoring Committee (DMC) from…

Tekada will import 50 mln doses of Moderna’s coronavirus vaccine candidate in Japan

2 mins read

The FINANCIAL — Takeda Pharmaceutical Company Limited announced that it will import and distribute 50 million doses of Moderna’s COVID-19 vaccine candidate, mRNA-1273, starting in the first half of 2021, pending licensure in Japan. This effort is part of a three-way agreement among Takeda, Moderna and the Government of Japan’s Ministry of Health Labour and…

PMI announced Medicago to supply up to 76 mln doses of its plant-derived coronavirus vaccine candidate

4 mins read

The FINANCIAL — Since 2008, Philip Morris Investments B.V. (PMIBV), a subsidiary of Philip Morris International (PMI) (NYSE: PM), has been a shareholder of Medicago (in which it currently holds an approximately one-third equity stake) and has supported Medicago’s innovative plant-derived research and development focused on vaccines. The investment is consistent with PMI’s own efforts to leverage science…